Anthrax antigenic compositions
1 Assignment
0 Petitions
Accused Products
Abstract
An antigenic pharmaceutical composition is provided comprising Protective Antigen (PA) and Lethal Factor (LF), wherein said PA and/or LF lacks a functional binding site, thereby preventing said PA and LF from binding together via said binding site or thereby preventing said PA from binding to a native PA cell receptor via said binding site, and wherein said composition is substantially non-toxic to animal cells. The composition is for preventing or minimising anthrax toxicity in mammals, preferably in humans. Also provided are DNA and RNA based vaccines encoding the antigenic components of said pharmaceutical composition. The present specification also describes antibodies that bind to at least one of PA, LF or EF, which binding thereby prevents:—(i) PA from binding to LF or EF, or to a native PA cell receptor; or (ii) LF from binding to PA; or (iii) EF from binding to PA.
16 Citations
46 Claims
-
1-21. -21. (canceled)
- 22. An antigenic pharmaceutical composition comprising 83 kDa Protective Antigen (PA) and Lethal Factor (LF), wherein PA lacks a functional binding site for a native PA cell receptor thereby preventing said PA from binding to said native cell receptor, and/or PA lacks a functional furin cleavage site thereby preventing said PA from in vivo cleavage by furin to form 63 kDa PA, and wherein said composition is substantially non-toxic to animal cells.
Specification